Replies to post #8013 on Cellectar Biosciences Inc (CLRB)

[Sluicebox]

Improves the ORR in all MM populations previous read out vs new read out i 60 mCi.

Tripple refractory 33% --> 40% >=60mci (the PR)
Quad/penta refractory 40% --> 53.8% >= 60mci
High Risk 50% 75 --> 62.5% >= 60 mci
6 or more lines prior 42.8% --> 47.1% >=60mci

NB!! trial continue to be ongoing - so dual dosing data coming up next ??

Sunofwolf, you been right about this stock for long, but reversal is here, get onboard and get a smile on your face :-)